Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04109859
Other study ID # KY201999
Secondary ID
Status Enrolling by invitation
Phase Phase 1
First received
Last updated
Start date April 1, 2019
Est. completion date January 21, 2021

Study information

Verified date September 2019
Source Southwest Hospital, China
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Increased production of vasodilating substances such as NO plays an important role in the development of vasoplegic syndrome caused by obstructive jaundice.Methylene blue plays a role in raising blood pressure by inhibiting the vasodilator Nitric Oxide (NO)


Description:

The level of circulating hydrogen sulfide (H2S) in patients with obstructive jaundice is significantly increased. As a direct opener of KATP channels in vivo, H2S also has diastolic peripheral vasculature . H2S participates in the occurrence of vasoplegic syndrome in patients with obstructive jaundice by interacting with NO. However, it is unclear whether methylene blue can relieve vasoplegic syndrome in patients with obstructive jaundice by inhibiting the vasodilating effect of substances such as H2S and NO.

Therefore, this clinical study intends to include patients with obstructive jaundice, using randomized, controlled, prospective study to explore the effect of methylene blue on the occurrence of vasoplegic syndrome, organ function and prognosis in patients with obstructive jaundice.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 64
Est. completion date January 21, 2021
Est. primary completion date January 21, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Age: 18~70 years old;

2. ASA grade I~III;

3. Ability to comply with research protocols;

4. Patients with obstructive jaundice: patients with total bilirubin greater than 50umol/L;

5. Voluntarily participate in the study and sign the informed consent form. -

Exclusion Criteria:

1. ASA IV~V grade;

2. women during lactation and pregnancy;

3. Patients with severe heart disease or lung disease before surgery;

4. Participating in other trials in the last 2 months;

5. Those whose mental state cannot cooperate, who suffer from mental illness, have no self-control, and cannot express clearly;

6. Those who refuse to sign the informed consent form. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Saline
When using saline, if found mean arterial pressure <65mmHg, Cardic Output>4L/min, Sequential Vascular Response<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
Methylene Blue
Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping

Locations

Country Name City State
China department of anesthesia, Southwest Hospital, Third Military Medical University Affiliation: Southwest Hospital, China ChongQing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Jiaolin Ning,MD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute physiology and chronic health evaluation IIScore sheet use this Score sheet to evaluation of postoperative organ function in patients.The total score is 0 to 71 3 days
See also
  Status Clinical Trial Phase
Completed NCT00383318 - Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia N/A
Completed NCT00360204 - Improving Health Outcomes for New Mothers and Babies Phase 3
Withdrawn NCT04021927 - Development of a Neonatal Jaundice Treatment Accelerator by Redirection of Unused Light During Phototherapy N/A
Completed NCT00966719 - Breastfeeding Support Intervention in Jaundiced Infants N/A
Completed NCT02033096 - Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
Terminated NCT01514058 - A Prospective, Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction N/A
Active, not recruiting NCT01683708 - Effectiveness Of Symbiotic Therapy In Jaundiced Patients N/A
Completed NCT01203410 - Prediction of Jaundice in Term Infants
Not yet recruiting NCT06232174 - Value of Transcutaneous Bilirubin Devices
Completed NCT01356030 - Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer N/A
Not yet recruiting NCT06276738 - The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease
Completed NCT02991339 - The Effects of Dexamethasone Administration on Jaundice Following Liver Resection Phase 2/Phase 3
Completed NCT02787512 - Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer N/A
Withdrawn NCT00240123 - Effect of Benadryl Sedation During ERCP or EUS Phase 1
Completed NCT02926131 - A Study to Evaluate a New Jaundice Stick Test
Completed NCT01499537 - Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct N/A
Active, not recruiting NCT02376907 - Biliary Drainage in Patients With Duodenal Metal Stent N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Recruiting NCT06173947 - SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
Active, not recruiting NCT04271176 - Jaundice as Initial Presentation of Liver Hydatidosis (ICTEHIDA)